Sartorius Stedim Biotech SA
PAR:DIM

Watchlist Manager
Sartorius Stedim Biotech SA Logo
Sartorius Stedim Biotech SA
PAR:DIM
Watchlist
Price: 175 EUR 3.8% Market Closed
Market Cap: 17B EUR
Have any thoughts about
Sartorius Stedim Biotech SA?
Write Note

Sartorius Stedim Biotech SA
Cash & Cash Equivalents

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Sartorius Stedim Biotech SA
Cash & Cash Equivalents Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Cash & Cash Equivalents CAGR 3Y CAGR 5Y CAGR 10Y
Sartorius Stedim Biotech SA
PAR:DIM
Cash & Cash Equivalents
€454.1m
CAGR 3-Years
21%
CAGR 5-Years
78%
CAGR 10-Years
27%
Pcas SA
PAR:PCA
Cash & Cash Equivalents
€266k
CAGR 3-Years
-67%
CAGR 5-Years
-50%
CAGR 10-Years
-27%
Eurofins-Cerep SA
PAR:ALECR
Cash & Cash Equivalents
€9.3m
CAGR 3-Years
45%
CAGR 5-Years
28%
CAGR 10-Years
-2%
No Stocks Found

Sartorius Stedim Biotech SA
Glance View

Market Cap
17B EUR
Industry
Life Sciences Tools & Services

Sartorius Stedim Biotech SA, a key player in the biopharmaceutical industry, has positioned itself at the forefront of innovation in bioprocessing and laboratory solutions. Established in the early 2000s through the merger of Sartorius AG's biotech division and Stedim S.A., the company’s mission centers on enabling the development and production of life-saving biologics. With a comprehensive portfolio that includes bioprocessing equipment, research services, and laboratory instruments, Sartorius caters to a vast array of customers, from small biotech firms to large pharmaceuticals, ensuring seamless workflows in drug development and manufacturing. By leveraging cutting-edge technologies and maintaining a commitment to sustainability, Sartorius has built a reputation as a trusted partner in the industry, addressing the growing demand for effective therapies amidst an ever-evolving healthcare landscape. As the global biopharmaceutical market expands, driven by advancements in personalized medicine and precision therapies, Sartorius is well-positioned to capitalize on these trends. The company’s recent strategic acquisitions and investments in digitalization and automation enhance its product offerings, allowing clients to improve efficiencies and reduce time-to-market for essential therapeutics. Boasting a strong financial track record and a commitment to research and development, Sartorius Stedim Biotech SA not only ensures consistent growth but also aligns with long-term health sector trends. For investors, this combination of strategic vision, robust market position, and innovative capabilities makes Sartorius an attractive investment opportunity in the booming biotechnology sector.

DIM Intrinsic Value
159.09 EUR
Overvaluation 9%
Intrinsic Value
Price

See Also

What is Sartorius Stedim Biotech SA's Cash & Cash Equivalents?
Cash & Cash Equivalents
454.1m EUR

Based on the financial report for Jun 30, 2024, Sartorius Stedim Biotech SA's Cash & Cash Equivalents amounts to 454.1m EUR.

What is Sartorius Stedim Biotech SA's Cash & Cash Equivalents growth rate?
Cash & Cash Equivalents CAGR 10Y
27%

Over the last year, the Cash & Cash Equivalents growth was 313%. The average annual Cash & Cash Equivalents growth rates for Sartorius Stedim Biotech SA have been 21% over the past three years , 78% over the past five years , and 27% over the past ten years .

Back to Top